Welcomes New Chairman of the Board and Announces

Welcomes New Chairman of the Board and Announces

Quarter 2019 Financial Results

Israel - August 28, 2019 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company

focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced the appointment of a new Chairman

of the Board of Directors and financial results for the quarter ended June 30, 2019.

Mark Germain, who has served as BiondVax's Vice Chairman of the Board of Directors since June 2018, has been appointed Chairman,

effective September 30, 2019. Based in New York, and having served as founder, director, chairman of the board, and/or investor

in over twenty biotech companies, and with experience assisting in arranging corporate partnerships, acquiring technology, entering

mergers and acquisitions, and executing financings, Mr. Germain is well suited to help guide BiondVax's ongoing corporate

development. Among his current positions, Mr. Germain is a Managing Director at The Aentib Group, a boutique merchant bank, and

serves as a director on the board of the Israeli company Pluristem Therapeutics Inc. (Nasdaq: PSTI). Professor Avner Rotman, who

has served as BiondVax's Chairman since 2005, will continue to serve as a Director.

Mr. Mark Germain commented: "It has been

a great pleasure to work with Ron and his team this past year, and the rest of the board, and I'm honored to be elected

Chairman at this exciting time for the company. Recent events have positioned BiondVax to become a successful manufacturer and

marketer of its M-001 universal flu vaccine candidate. In July we closed on a financing of US$20M predominantly supported by our

largest shareholder, Marius Nacht, bringing his ownership in the company to approximately 42%. This financing, the 24 million

Euros made available by the European Investment Bank, and other resources now provide us with the means to complete our Phase

3 pivotal trial (with a total of approximately 12,000 participants), scale up manufacturing and begin preparation for commercialization."

Dr. Ron Babecoff, BiondVax's President and CEO, commented,

"I have had the pleasure of working closely with Mark Germain since he joined our Board of Directors last year. I am

confident that his experience and knowledge of the pharmaceutical ecosystem, in addition to his relevant international connections,

will prove beneficial as we progress through our ongoing pivotal clinical efficacy Phase 3 trial, and upscale production capacity

in our manufacturing facility."

Babecoff noted, "Over Professor Rotman's term as Chairman, BiondVax has grown from a preclinical company

to a Nasdaq-listed company. On a personal note, I wish to thank Avner for his leadership, guidance, and support that helped me

and the company navigate through the many challenges we encountered over the years."

Quarter 2019 Financial Summary

are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.566 (NIS/$US) as at

of June 30, 2019, BiondVax had cash and cash equivalents of NIS 33.9 million ($9.5 million) as compared to NIS 75.9m as of December

31, 2018. Expenses are related to execution of planned ongoing operations including the ongoing pivotal, clinical efficacy, Phase

3 trial of the Company's M-001 Universal Flu Vaccine candidate, and construction of a mid-size commercial manufacturing

facility. These figures do not include the $20 million raised in a rights offering that concluded near the beginning of Q3 in

(NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate,

called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic

influenza. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides

intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed

Phase 1/2 and Phase 2 clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.

The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity.

Please visit www.biondvax.com.

E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements reflect the management's current views with respect to certain current and future events and

are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected

by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and

outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new

manufacturing facility; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing

approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the

Company to maintain, preserve and defend its intellectual property and patents granted; whether our vaccine candidate will successfully

advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and

Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise

capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the

heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2018 filed with the U.S.

Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's

periodic filings with the SEC. We undertake no obligation to revise or update any forward-looking statement for any reason.

thousands, except per share data

an amount lower than NIS 1.

OF COMPREHENSIVE INCOME

thousands, except per share data